Blood Res  
Mantle cell lymphoma relapsed after autologous stem cell transplantation: a single-center experience
Aaron Wu1*, Solomon A. Graf1,2,3*, Nicholas Burwick1,4, Jonathan E. Grim1,2,3, Zhao Ming Dong1,5, Robert E. Richard1,4, Thomas R. Chauncey1,2,3
1Department of Hospital and Specialty Medicine, Veterans Affairs Puget Sound Health Care System, 2Division of Oncology, University of Washington Medicine, 3Clinical Research Division, Fred Hutchinson Cancer Research Center, 4Division of Hematology, 5Division of Pathology, University of Washington Medicine, Seattle, WA, USA
Correspondence to: Thomas R. Chauncey, M.D., Ph.D.
Veterans Affairs Puget Sound Health Care System, Oncology (111) 1660 S. Columbian Way, Seattle, WA 98108,

*These authors contributed equally to this work.
Published online: March 13, 2020.
© The Korean Journal of Hematology. All rights reserved.

Background: Autologous stem cell transplantation (autoSCT) can extend remission of mantle cell lymphoma (MCL), but the management of subsequent relapse is challenging.
Methods: We examined consecutive patients with MCL who underwent autoSCT at Veterans Affairs Puget Sound Health Care System between 2009 and 2017 (N=37).
Results: Ten patients experienced disease progression after autoSCT and were included in this analysis. Median progression free survival after autoSCT was 1.8 years (range, 0.3–7.1) and median overall survival after progression was only 0.7 years (range, 0.1 to not reached). The 3 patients who survived more than 1 year after progression were treated with ibrutinib.
Conclusion: Our findings suggest that ibrutinib can achieve relatively prolonged control of MCL progressing after autoSCT.
Keywords: Mantle cell lymphoma, Autologous stem cell transplant, Real-world


This Article

Current Issue


Indexed/Covered by

Today : 38  /
Total : 190,574